J Clin Oncol 2005, 23:694–704.PubMedCrossRef 3. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PL, Kolstad A, d’Amore F, Diaz MG, Petrini M, Sebban C, Zinzani PL, van Oers MHJ, van Putten W, Bischof-Delaloye
A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A: Phase III trial of consolidation therapy with Yttrium-90-Ibritumomab tiuxetan compared LB-100 concentration with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008, 26:5156–5164.PubMedCrossRef 4. Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof-Delaloye A: Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin’s lymphoma: A review of the evidence. The Oncologist 2009, 14:17–29.PubMedCrossRef 5. Witzing TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS: Safety of Yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-Hodgkin’s lymphoma. J Clin Oncol 2003, 21:1263–1270.CrossRef 6. Emmanouilides C, Witzing TE, Gordon LI, Vo K, Wiseman GA, Flinn IW, Darif M, Schilder RJ, Molina A: Treatment with Yttrium-90 ibritumomab tiuxetan at early relapse is safe and effective
in patients with previously treated B-cell non-Hodgkin’s lymphoma. Leuk Lymphoma 2006, 47:629–636.PubMedCrossRef 7. Witzing TE,
Molina A, Gordon LI, Emmanouilides C, Schilder RJ, Flinn IW, Darif NU7026 M, Macklis R, Vo K, Wiseman GA: Long-term responses in patients with recurring or refractory B-cell non-Hodgkin’s lymphoma treated with Yttrium-90 ibritumomab tiuxetan. Cancer 2007, 109:1804–1810.CrossRef 8. Leonard JP, Coleman M, Kostakoglu L, selleck compound Chadbum A, Cesarman E, Furman RR, Schuster MW, Niesvizky R, Muss D, Fiore J, Kroll S, Tidmarsh G, Vallabhajosula S, Goldsmith SJ: Abbreviated chemotherapy with fludarabine followed Obeticholic Acid concentration by tositumomab and iodine I-131-tositumomab for untreated follicular lymphoma. J Clin Oncol 2005, 23:5696–5704.PubMedCrossRef 9. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, Fisher RI: Phase II trial of CHOP chemotherapy followed by I-131-tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: Five years follow up of Southwest Oncology Group Protocol 59911. J Clin Oncol 2006, 24:4143–4129.PubMedCrossRef 10. Sacchi S, Pozzi S, Marcheselli R, Federico M, Tucci A, Merli F, Orsucci L, Liberati M, Vallisa D, Brugiatelli M: Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. Cancer 2007, 110:121–128.PubMedCrossRef 11.